Bracco, Novation partner for MR contrast agents
Bracco Diagnostics and Novation, a healthcare group purchasing organization, have signed an agreement making available Bracco’s MRI contrast media products to VHA, University HealthSystem Consortium and Provista members represented by Novation, through March 2010.

The agreement includes Bracco’s MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, approved in the United States for central nervous system (CNS) MRI, as well as ProHance (gadoteridol) injection, 279.3 mg/mL, a macrocyclic MR contrast agent available in the United States since 1992, according to Bracco.

The agreement is effective Oct. 1 and extends through March 31, 2010, according to the Irving, Texas-based Novation.